<DOC>
	<DOCNO>NCT00263315</DOCNO>
	<brief_summary>A Phase II/III randomize double-blind study compare safety efficacy weekly administration 25 mg nebulized AmBisome nebulized placebo solution prevent invasive pulmonary aspergillosis neutropenic hemato-oncologic patient .</brief_summary>
	<brief_title>Inhalation Liposomal Amphotericin B Prevent Invasive Aspergillosis</brief_title>
	<detailed_description>The morbidity , mortality cost invasive pulmonary aspergillosis ( IPA ) neutropenic patient high . An effective intervention prevent IPA would therefore welcome . The incidence IPA neutropenic hematology patient institution recently estimate 5-10 % . Currently , HEPA filtration routinely use prevention IPA . In 1988 , Schmitt et al . show significant delayed mortality rat model IPA rat treat aerosolized conventional amphotericin-B ( amB ) two day infection ( 1 ) . Conventional amB may interfere surfactant function lung . In contrast , liposomal amphotericin-B contains phospholipid structurally relate surfactant inhibits natural surfactant function slightly . Furthermore , rat , mean concentration AmB lungs 3.7 time high day one almost 6 time higher day seven single dose treatment aerosolize liposomal amB compare conventional AmB ( 2 ) . Only one non-placebo control randomized clinical trial evaluate prophylactic use inhalation therapy conventional amB prevention IPA non-significant 43 % reduction observe ( 3 ) . We postulate weekly inhalation liposomal AmB neutropenic hematology patient prevent IPA . In randomised placebo control clinical trial compare safety efficacy administration nebulized liposomal AmB ( 2x/week ) placebo prevention IPA haematological patient expect duration neutropenia &gt; 10d . To demonstrate reduction incidence invasive pulmonary aspergillosis 7 % 1 % , total 170 neutropenic episode arm include ( power 80 % , two-tailed alfa=0.05 ) . The primary efficacy endpoint cumulative percentage patient develop proven probable IPA . Per protocol serum galactomannan level monitor 2x/week HR-CT lung perform unexplained fever ( &gt; 5d ) unresponsive broad-spectrum antibiotic therapy . EORTC/MSG criterion use diagnosis IPA . The primary safety endpoint premature discontinuation study drug &gt; 1week due intolerance .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>1 . Male female hospitalize patient age &gt; 18 yr 2 . The patient hematologic malignancy receive bonemarrow transplant 3 . The patient start course chemotherapy within 4 day already neutropenic admission 4 . The expected duration severe neutropenia ( PMN &lt; 0.5x10*9/L ) follow study entry &gt; 10 day 5 . The patient receive oral antibiotic prophylaxis fluconazole 6 . Written inform consent obtain 1 . The patient show evidence pulmonary fungal infection fungal sinusitis trial entry 2 . The concomitant use systemic antiaspergillus treatment itraconazole intravenous formulation amphotericin B study entry 3 . Known hypersensitivity amphotericin B 4 . Any evidence pneumonia pneumonitis trial entry 5 . Any impossibility use nebulizer properly 6 . Expected survival &lt; 3 month entry 7 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>aspergillosis</keyword>
	<keyword>mycosis</keyword>
	<keyword>neutropenia</keyword>
	<keyword>primary prevention</keyword>
	<keyword>hematologic disease</keyword>
	<keyword>amphotericin B</keyword>
	<keyword>AmBisome</keyword>
	<keyword>liposomal amphotericin B</keyword>
</DOC>